Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | KIT | P10721 | 7/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19521293 | 0.85 | EPHX2 (0.42) | BRD4BRPF1CA12CA1CA2 | |
| SCHEMBL18112985 | 0.84 | CYP17A1 (0.48) | BRD4KITBRPF1CA12CA1 | |
| SCHEMBL16015104 | 0.83 | CA1 (0.44) | KITCA12CA1CA2CA3 | |
| SCHEMBL19748468 | 0.81 | BRD4 (0.39) | BRD4BRPF1CA12CA1CA2 | |
| SCHEMBL5198232 | 0.79 | CA1 (0.64) | BRD4BRPF1CA12CA1CA2 | |
| SCHEMBL1075440 | 0.77 | OPRM1 (0.46) | BRD4KITBRPF1CA12CA1 | |
| SCHEMBL29703832 | 0.75 | EGFR (0.38) | CA12CA1CA2CA3CA4 | |
| SCHEMBL20091532 | 0.75 | EGFR (0.38) | CA12CA1CA2CA3CA4 | |
| SCHEMBL24747207 | 0.75 | BACE1 (0.46) | — | |
| SCHEMBL29891118 | 0.75 | BACE1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111916-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2018-04-26 | — | — | US | disclosed |
| WO-2016161145-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016161145-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111916-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | STK4, STK3, STK11 | BRD4 695/4885KIT 557/4885BRPF1 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.